Nigeria sovereign health unit and Roche partner on 12-site lab rollout
The healthcare arm of Nigeria’s sovereign wealth fund has signed a five-year deal with Roche Diagnostics to build automated laboratory infrastructure, highlighting the growing role of public-private partnerships in closing emerging market healthcare funding gaps.
MedServe, the healthcare subsidiary of the Nigeria Sovereign Investment Authority, has signed a five-year agreement with Roche Diagnostics to deploy automated laboratory systems across 12 sites in Nigeria. Installation at the first facility is already underway as part of the initial phase of a broader expansion into diagnostic and oncology services.
Under the terms of the partnership, the Swiss pharmaceutical giant will supply the laboratory equipment and implementation support. MedServe will provide the capital and local management to establish integrated diagnostic services designed to operate sustainably within the domestic healthcare framework.
The initiative will repurpose existing HIV testing infrastructure to accelerate the expansion of overall laboratory capacity. This strategy aligns with broader national healthcare priorities while addressing urgent domestic funding constraints.
For investors and market observers, the deal underscores a critical shift in how emerging economies approach healthcare infrastructure. Rather than relying on external capacity, African nations are increasingly utilizing sovereign investment vehicles to attract foreign technical expertise and build resilient domestic systems.
Tolulope Adewole, managing director and chief executive officer of MedServe, emphasized the macroeconomic and social importance of the rollout. “Expanding Nigeria’s diagnostic services is a vital part of building a healthcare system that can respond more effectively to the needs of its people,” he said.
Adewole noted that the agreement combines local leadership, investment and technical expertise to enhance laboratory services across the country. MedServe currently operates three flagship centres and is spearheading the development of a nationwide network combining advanced medical technology with clinical governance.
Roberto Taboada, network head for Anglo-West Africa at Roche Diagnostics, highlighted the necessity of localized execution for long-term viability. “Building lasting diagnostic capability requires strong local partnerships and consistent support through implementation,” Taboada stated.
He added that collaborating with MedServe allows Roche to contribute its expertise to a programme shaped around Nigeria’s specific priorities. The partnership aims to introduce modern automated testing systems while simultaneously training local personnel to ensure sustained operation.
The collaboration arrives as global healthcare systems navigate severe funding pressures. Both companies argue that such public-private models will become increasingly essential for expanding medical capacity and improving access to essential services in developing markets.
